Cold atmospheric plasma-activated liquid inhibits peritoneal metastasis in drug-resistant ovarian cancer by targeting the epithelial-mesenchymal transition
Authors:
- 7 August 2025
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 42 (5) , 1-20
Abstract
Ovarian cancer remains a significant challenge in oncology due to its aggressive nature, late-stage diagnosis, and high rates of chemoresistance, particularly to platinum-based therapies like cisplatin. The epithelial-mesenchymal transition (EMT) is a key driver of ovarian cancer metastasis and drug resistance, highlighting the need for novel therapeutic strategies. Cold atmospheric plasma (CAP) and plasma-activated liquids (PAL), including plasma-activated medium (PAM) and saline (PAS), have emerged as promising anticancer agents, generating reactive oxygen and nitrogen species (RONS) that selectively target cancer cells. This study investigates the potential of PAL to inhibit the invasion and metastasis of cisplatin-resistant ovarian cancer cells and explores its synergistic effects with cisplatin. In vitro, PAM reduced proliferation, migration, and invasion of cisplatin-resistant ovarian cancer cells (A2780/DDP and SKOV3/DDP) while downregulating EMT-related proteins (N-cadherin, β-catenin, vimentin). H2O2 in PAM inhibit the PI3K/AKT/GSK3β pathway, promoting degradation of EMT regulators Snail, Slug, and β-catenin. Combining PAM with cisplatin enhanced therapeutic efficacy, reducing cell viability and metastatic potential. In vivo studies using an orthotopic mouse model further confirmed that PAS combined with low-dose cisplatin effectively suppressed tumor growth and metastasis with minimal side effects. These findings underscore the potential of PAL as an adjuvant therapy for cisplatin-resistant ovarian cancer, offering a novel approach to overcome drug resistance and inhibit metastasis. Future research should focus on optimizing treatment protocols and elucidating the molecular mechanisms underlying the synergistic effects of PAL and cisplatin.Keywords
Funding Information
- Natural Science Foundation of Shaanxi Province (2022JQ-882)
- Project of Independent Innovative Experiment for Postgraduates in Medicine in Xi’an Jiaotong University (YJSCX-2023-010)
- Natural Science Basic Research Plan in Shaanxi Province (2024JC-YBMS-785, 2025JC-YBMS-860)
- Fundamental Research Funds for the Central Universities (xtr062024007)
- Scientific Research Project of Shaanxi Provincial Administration of Traditional (SZY-KJCYC-2023-084)
This publication has 77 references indexed in Scilit:
- Wnt/β-catenin-driven EMT regulation in human cancersCellular and Molecular Life Sciences, 2024
- Redox signaling-mediated tumor extracellular matrix remodeling: pleiotropic regulatory mechanismsCellular Oncology, 2023
- Nanosecond pulsed cold atmospheric plasma jet suppresses proliferation and migration of human glioblastoma cells via apoptosis promotion and EMT inhibitionArchives of Biochemistry and Biophysics, 2023
- Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum ResistanceJAMA Oncology, 2023
- Comparison of direct and indirect low‐temperature plasma triggering immunogenic cell death in B16F10 melanomaPlasma Processes and Polymers, 2023
- Cancer of the ovary, fallopian tube, and peritoneum: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- Plasma‐activated medium induces apoptosis in chemotherapy‐resistant ovarian cancer cells: High selectivity and synergy with carboplatinPlasma Processes and Polymers, 2021
- Cold Atmospheric Pressure Plasma Sources for Cancer Applications2020
- New strategies in ovarian cancer treatmentCancer, 2019
- Ovarian cancer: Current status and strategies for improving therapeutic outcomesCancer Medicine, 2019